We intervene at the highest-value, highest-friction steps of the drug discovery value chain. The highlighted steps are where we replace or dramatically accelerate the current bottleneck.
Highlighted = primary intervention zones. Shaded = downstream value through companion diagnostics & pharmacogenomics.
| Stage | Traditional Approach | Our Platform | Time Savings | Cost Reduction |
|---|---|---|---|---|
| Target ID | Literature mining, manual GWAS, 12–18 months | OmicsOS multiomics integration, AI target scoring, India cohort validation | 70% faster | 60% lower |
| Hit Discovery | HTS library screening, $2–5M, 6–12 months | Virtual screen + focused FAL validation of top 500 candidates | 65% faster | 80% lower |
| Lead Optimization | Manual SAR iterations, 18–36 months | Closed-loop DBTL: AI designs → FAL makes → AI learns → iterate | 50% faster | 50% lower |
| Preclinical Biomarker | $5–10M, 2–3 years per panel | scRNA + spatial omics + proteomics panel in 6–9 months | 60% faster | 70% lower |